All articles by Miranda Mclaren

Why Timelines Break Down in Rare Kidney Drug Development

Enrollment challenges continue to be a defining constraint in nephrology research. In a January 2026 snapshot of GlobalData’s clinical trial…
The hidden bottleneck in digital healthcare: Why hospital wireless networks are under pressure in 2026

Healthcare is entering a new era of digital transformation. In the US, competition among leading providers is driving rapid adoption…
CGT’s next obstacle: Securing the leukapheresis supply chain

Clinical trial numbers for CAR-T therapies have risen dramatically in recent years, and as these programmes expand beyond oncology into…
From compliance to culture: Lessons from a quality leader on pharma’s next imperative

We spoke with Grace Breen, Senior Vice President, Quality at Sharp about the role of quality in a CDMO environment,…
Extracellular vesicles: The next frontier in regenerative medicine and drug delivery?

Extracellular vesicles (EVs) are tiny, membrane-bound particles released by every cell type studied to date. Though small, they carry a…

Dermatology Trials by the Numbers: Key Trends and Benchmarks for 2026

Dermatology - spanning chronic inflammatory disease, infection, wound healing, pigment disorders, hair loss and rare genetic conditions - is nothing…
Year in review: EmVenio in 2025

From a rebrand to clinical trial facilitation to the conference circuit, EmVenio covered a lot of ground. Here are some…
Potency assays in cell therapies: A look behind the challenges

Dr. Scott Jones has spent more than 35 years advancing assay development and currently leads BioBridge Global’s R&D department. His…
Clinical trial predictions and the role of technology in 2026

Looking ahead to 2026, the clinical research landscape is entering a pivotal phase. As trial design innovations, hybrid studies, and…
Meet the new EmVenio in 2026

Clinical research is evolving, but access to trials remains uneven. Many patients still face barriers to participation, and sponsors are…

Sections